Bearish Options Activity in Snyder's-Lance (LNCE) Targeting Downside Below $30/Share -Susquehanna

SunTrust Robinson Humphrey Downgrades Lance, Inc. (LNCE) to Hold

SunTrust Robinson Humphrey downgraded Lance, Inc. (NASDAQ: LNCE) from Buy to Hold with a price target of $30.00.

The analyst believes the company's underlying issues such as higher promo levels and lower manufacturing will persist indefinitely. The analyst sees limited catalysts.

For... More

Pre-Open Movers 04/17: (CBLI) (ALR) (STRP) Higher; (OMED) (LNCE) (INCY) Lower (more...)

Today's Pre-Open Stock Movers

Cleveland BioLabs, Inc. (NASDAQ: CBLI) 38.7% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has completed its review of a side-by-side analytical comparison of two formulations of entolimod. The FDA agreed with CBLI that these data indicate the in vitro analytical comparability of the formulations. Based on the outcome of its review, the FDA has provided CBLI with its consent for initiation of an in vivo biocomparability study of these formulations in non-human primates (NHP).

HTG Molecular Diagnostics, Inc. (Nasdaq:... More

Snyder's-Lance Inc. (LNCE) Warns for Q1, Confirm CEO Transition Plan

(Updated - April 17, 2017 6:11 AM EDT)

Snyders-Lance, Inc. (NASDAQ: LNCE) today announced a CEO transition and reported preliminary unaudited financial results for the first quarter ended April 1, 2017.

CEO Transition Underway

Snyders-Lance, Inc. has announced that its President and CEO, Carl E. Lee, Jr., has retired after 12 years of service to the Company. Brian J. Driscoll, former President and CEO of Diamond Foods and a current Director of Snyders-Lance, has agreed to step in as interim CEO.

In announcing the transition, Chairman of the Board, James Johnston said the... More